Key Epilepsy Trial Results Coming: Rapport's RAP-219 Phase 2a Data Could Impact Treatment

Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing precision medicines for neurological and psychiatric disorders, has scheduled a conference call and webcast for September 8, 2025, at 8:00 am ET. The company will present topline results from its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.

Investors can access the call through a webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations using conference ID 4762775. A replay will be available on the company's website for 90 days after the call.

https://www.stocktitan.net/news/RAPP/rapport-therapeutics-to-announce-topline-results-for-rap-219-phase-e5og23e8a46n.html